Search Result

Results for "

docetaxel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) ADC Linker (1) Aldehyde Dehydrogenase (ALDH) (1) Androgen Receptor (2) Apoptosis (8) Biochemical Assay Reagents (1) Cytochrome P450 (1) DYRK (1) Endogenous Metabolite (3) HIF/HIF Prolyl-Hydroxylase (1) Integrin (1) Isotope-Labeled Compounds (1) Microtubule/Tubulin (9) PSMA (1) Survivin (1)
By Research Areas:	Cancer (25)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0011

*Docetaxel* Maximum Cited Publications 81 Publications Verification RP-56976	Microtubule/Tubulin Apoptosis Endogenous Metabolite	Cancer
Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-16674

10-Oxo Docetaxel docetaxel Impurity 1	Microtubule/Tubulin	Cancer
10-Oxo Docetaxel (Docetaxel Impurity 1) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.

HY-16675

7-Epi-10-oxo-docetaxel docetaxel Impurity 2	Microtubule/Tubulin	Cancer
7-Epi-10-oxo-docetaxel (Docetaxel Impurity 2) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).

HY-B0011S

Docetaxel-d9 RP-56976-d₉	Microtubule/Tubulin Apoptosis Endogenous Metabolite	Cancer
Docetaxel-d₉ is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].

HY-B0011R

Docetaxel (Standard) RP-56976 (Standard)	Microtubule/Tubulin Apoptosis Endogenous Metabolite	Cancer
Docetaxel (Standard) is the analytical standard of Docetaxel. This product is intended for research and analytical applications. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011A

Docetaxel Trihydrate Maximum Cited Publications 81 Publications Verification RP-56976 Trihydrate	Microtubule/Tubulin Apoptosis	Cancer
Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC₅₀ value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .

HY-B0011AS

Docetaxel-d5 trihydrate RP-56976-d₅ trihydrate	Isotope-Labeled Compounds Microtubule/Tubulin Apoptosis	Cancer
Docetaxel-d₅ (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].

HY-B0018

Docetaxal 2 Publications Verification 10-Acetyl docetaxel; PNU-101383	ADC Cytotoxin	Cancer
Docetaxal (10-Acetyl docetaxel) is an analog of Docetaxel (HY-B0011), with anticancer activity. Docetaxel is a microtubule disassembly inhibitor, with antimitotic activity .

HY-16676

7-Epi-docetaxel

4-epi-docetaxel; 7-Epidocetaxel; 7-Epitaxotere
Microtubule/Tubulin Cancer

7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.
HY-W778546

7-epi-10-Deacetyl baccatin III

Others Cancer

7-epi-10-Deacetyl baccatin III can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

7-Epi-docetaxel 4-epi-docetaxel; 7-Epidocetaxel; 7-Epitaxotere	Microtubule/Tubulin	Cancer
7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.

7-epi-10-Deacetyl baccatin III	Others	Cancer
7-epi-10-Deacetyl baccatin III can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-W778547

7-epi-10-Oxo-10-deacetyl baccatin III 10-Dehydrobaccatin V	Others	Cancer
7-epi-10-Oxo-10-deacetyl baccatin III (10-Dehydrobaccatin V) can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-149894

MC-1-F2	Biochemical Assay Reagents	Cancer
MC-1-F2 is a FOXC2 inhibitor that reduces epithelial-mesenchymal transition (EMT) markers in breast cancer cells, suppresses cancer stem cell (CSC) properties and reduces invasiveness in castration-resistant prostate cancer (CRPC) cells. There is a synergistic effect between MC-1-F2 and Docetaxel, which has the potential to be used in combination to study CRPC .

HY-115677

ILK-IN-3	Integrin DYRK	Cancer
ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model .

HY-W019939

Hydroxy-PEG10-Boc	ADC Linker	Cancer
Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024) . Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011) .

HY-144670

ALDH3A1-IN-1	Aldehyde Dehydrogenase (ALDH)	Cancer
ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC₅₀ of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with docetaxel .

HY-122678

LQZ-7F	Survivin Apoptosis	Cancer
LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC₅₀s of 2.99 and 2.47 µM, respectively .

HY-145616

Sudocetaxel

Microtubule/Tubulin Cancer

Sudocetaxel is a microtubule depolymerization inhibitor for pH-sensitive docetaxel delivery.

Sudocetaxel	Microtubule/Tubulin	Cancer
Sudocetaxel is a microtubule depolymerization inhibitor for pH-sensitive docetaxel delivery.

HY-103591

DUPA(OtBu)-OH 1 Publications Verification	PSMA	Cancer
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

HY-145441

GEM–IB	Others	Cancer
GEM–IB is the conjugate of gemcitabine (GEM)-5'-phosphate with ibandronate (IB). GEM–IB as a single agent or in combination with Docetaxel (DTX) demonstrates reduced tumor burden, preservation of the bone architecture, and improved the survival in a murine model of osteosarcoma (OS) .

HY-B0022

Flutamide 5 Publications Verification SCH 13521	Androgen Receptor	Cancer
Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .

HY-119001

BKM1644	Others	Cancer
BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .

HY-125374

Larotaxel XRP9881	Apoptosis	Cancer
Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel .

HY-B0022R

Flutamide (Standard) SCH 13521 (Standard)	Androgen Receptor	Cancer
Flutamide (Standard) is the analytical standard of Flutamide. This product is intended for research and analytical applications. Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .

HY-157942

CYP1B1-IN-7	Cytochrome P450	Cancer
CYP1B1-IN-7 (compound 2a) is a selective inhibitor of CYP1B1 (IC₅₀: 75 nM). CYP1B1-IN-7 also reverses resistance (IC₅₀: 29 μM) and exhibits cytotoxicity in the CYP1B1-overexpressing MCF-7 cell line that is resistant to Docetaxel (HY-B0011) .

HY-16187

EL-102	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0011

*Docetaxel* 80+ Cited Publications RP-56976	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Microtubule/Tubulin Apoptosis Endogenous Metabolite
Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-B0011R

Docetaxel (Standard) RP-56976 (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Microtubule/Tubulin Apoptosis Endogenous Metabolite
Docetaxel (Standard) is the analytical standard of Docetaxel. This product is intended for research and analytical applications. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC₅₀ of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .

HY-W778546

7-epi-10-Deacetyl baccatin III	Structural Classification Terpenoids Source classification Taxaceae Diterpenoids Plants Taxus baccata L.	Others
7-epi-10-Deacetyl baccatin III can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

HY-W778547

7-epi-10-Oxo-10-deacetyl baccatin III 10-Dehydrobaccatin V	Structural Classification Terpenoids Source classification Taxaceae Diterpenoids Plants Taxus baccata L.	Others
7-epi-10-Oxo-10-deacetyl baccatin III (10-Dehydrobaccatin V) can be isolated from the degradation impurities in Docetaxel (HY-B0011) .

Cat. No.	Product Name	Chemical Structure

HY-B0011S

Docetaxel-d9
Docetaxel-d₉ is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].

HY-B0011AS

Docetaxel-d5 trihydrate
Docetaxel-d₅ (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].

Docetaxel-d5 trihydrate

Docetaxel-d₅ (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks